Department of Internal Medicine 1, Faculty of Medicine, Shimane University, Izumo, Japan.
The Center for Integrated Kidney Research and Advance, Faculty of Medicine, Shimane University, Izumo, Japan.
J Diabetes Investig. 2024 May;15(5):525-540. doi: 10.1111/jdi.14152. Epub 2024 Mar 8.
The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long-term influence of hypoglycemic drugs on cancer incidence and the safety for cancer-bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'.
多年来，2 型糖尿病与某些癌症风险之间的关联一直备受关注。然而，糖尿病药物对癌症发展的影响尚不完全清楚。前瞻性临床试验尚未阐明降糖药物对癌症发病率的长期影响，也没有阐明糖尿病伴癌患者的安全性，而大量临床前研究表明，除了血糖控制作用外，抗糖尿病药物还可能对致癌过程产生影响。由于没有关于抗糖尿病药物对癌症生物学安全性的证据，因此在为患有糖尿病和现有肿瘤的患者开任何药物时都需要仔细考虑。在这篇综述中，我们讨论了每种糖尿病治疗方法在癌症“起始”、“促进”和“进展”中的潜在影响。
